Patient Square Capital

2884 Sand Hill Road
Menlo Park, CA 94025

Website: patientsquarecapital.com

Firm Size

• Assets Under Management (AUM):$7.9 Billion
• Number of Funds:20
• Employees:53
• Firm Type:Private Equity
• Focus Areas: Software & Technology
  Services
  Healthcare
  

Description

Patient Square Capital is a private equity firm based in Menlo Park, California. The company focuses on investments in the healthcare sector, specifically in biopharmaceuticals, medical technology, and healthcare services. Patient Square Capital provides capital and strategic support to high-growth companies in the healthcare industry, aiming to enhance patient outcomes and drive innovation. With a team of experienced professionals, the firm aims to create value for its portfolio companies through active management and operational improvements. Overall, Patient Square Capital is dedicated to fostering advancements in the healthcare sector through its investments and expertise.

Latest News

Powered by

Feb 27, 2024: Elevage Medical Technologies Continues Expansion of Investment Team and Board
  Elevage Medical Technologies ("Elevage"), a portfolio company of Patient Square Capital , dedicated to supporting growth-stage medical device and medical technology companies, today announced key additions to the investment team and board. Vice-Presidents Suchira Sharma and Peter Tortora join the Elevage investment team, along with Dr. Josh Makower , a Senior Advisor to Patient Square and Elevage, who will also join the Elevage Board of Directors.

Jan 16, 2024: Enavate Sciences Hires Christine Del Corsano as Chief Financial Officer
  Enavate Sciences , a portfolio company of  Patient Square Capital , is pleased to announce that Christine Del Corsano has joined the firm as their Chief Financial Officer. Ms. Del Corsano reports to James Boylan, Chief Executive Officer of Enavate Sciences, and will oversee finance and operations for the firm and will partner with the executive team on corporate strategy.

Jan 02, 2024: Enavate Sciences Backs Graviton Bioscience in Financing Round to Advance Development of Selective ROCK2 Inhibitors
Graviton Bioscience, a privately held clinical-stage biotechnology company focused on therapies that inhibit Rho/Rho-associated coiled-coil containing protein kinase 2 (ROCK2) announced completion of financing from Enavate Sciences , a portfolio company of Patient Square Capital .  Proceeds from Enavate's investment will help to advance clinical development of GV101 and Graviton's pipeline of ROCK2 inhibitors to treat a range of serious fibrotic, inflammatory and neurologic conditions.

Dec 28, 2023: STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger - CERE, WAVD, ICVX, EAR
  Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated  Top 50  in the 2018-2022 ISS Securities Class Action Services Report and headquartered at the  Empire State Building in New York City , is investigating:

Dec 27, 2023: SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EAR, IMGN, CVLY
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

Dec 20, 2023: SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into Eargo, Inc.
 The following statement is being issued by Levi & Korsinsky, LLP:

Dec 04, 2023: Sara Nayeem, M.D., Experienced Biopharmaceutical Venture Investor, Joins Enavate Sciences as Executive Vice President, Investments
Enavate Sciences , a portfolio company of Patient Square Capital , is pleased to announce that Sara M. Nayeem , M.D. has joined the firm as Executive Vice President, Investments. Dr. Nayeem reports to James Boylan , Chief Executive Officer of Enavate Sciences, and will serve an integral role in the origination, evaluation, and selection of Enavate investments, as well as support Enavate partner companies on governance, partnerships, fundraising, and other strategic initiatives.

Nov 07, 2023: SHAREHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger - DOC, EAR, PATI, BBAI


Oct 30, 2023: SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EAR, SUM, PXD
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

Oct 30, 2023: Shareholder Alert: Ademi LLP investigates whether Eargo, Inc. has obtained a Fair Price in its transaction with Patient Square Capital
Ademi LLP is investigating Eargo (Nasdaq: EAR) for possible breaches of fiduciary duty and other violations of law in its transaction with Patient Square Capital .

Sep 21, 2023: Patient Square Capital Appoints David Katz as a Partner
  Patient Square Capital , a leading health care investment firm, today announced that David Katz has been named a Partner of the firm. Prior to joining Patient Square, Mr. Katz served as an advisor and Investment Committee member of The Pritzker Organization.  Prior to The Pritzker Organization, he spent nine years as a Managing Director at GTCR, where he co-led the Health Care team and served as a member of the firm's Investment Committee. At Patient Square, Mr. Katz will be instrumental in identifying investment opportunities to help patient-centric health care companies grow and thrive.

Jul 27, 2023: Patient Square Capital Appoints Clinical and Public Health Leader Kelvin A. Baggett, M.D., M.P.H., M.B.A., to Lead Newly Formed EMPIRIC Institute for Measuring Patient Impact
Patient Square Capital ("Patient Square"), a leading health care investment firm, today announced the formation of the EMPIRIC Institute™ ("EMPIRIC") and the appointment of physician and health care leader Kelvin A. Baggett , M.D., M.P.H., M.B.A., as Managing Director, Head of Patient Impact and Chair of the EMPIRIC Institute.

Jun 23, 2023: SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Acquisition of Syneos Health Inc. by a consortium of private investment firm affiliates com
The following statement is being issued by Levi & Korsinsky, LLP:

Jun 17, 2023: ALERT: The M&A Class Action Firm Continues Investigating the Merger - SYNH, FRG, AAIC, NEX
Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated  Top 50  in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the  Empire State Building in New York City , is investigating:

Jun 15, 2023: SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SYNH, DM, TESS, ISEE
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: